2006
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV
Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. Journal Of Antimicrobial Chemotherapy 2006, 58: 1299-1302. PMID: 17032686, DOI: 10.1093/jac/dkl399.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesAntibiotics, AntitubercularAnti-HIV AgentsBenzoxazinesCD4 Lymphocyte CountChromatography, High Pressure LiquidCyclopropanesDidanosineDrug Therapy, CombinationFemaleHIV InfectionsHumansLamivudineLongitudinal StudiesMaleOxazinesRifampinTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsExcellent clinical outcomesEfavirenz concentrationsClinical outcomesAntiretroviral therapyEfavirenz levelsAfrican patientsNon-detectable viral loadSmear-positive pulmonary TBLong-term clinical outcomesAdministration of efavirenzCD4 cell increaseHIV clinical outcomesPlasma efavirenz concentrationsCells/mm3Half of patientsTB regimenPulmonary TBPharmacokinetic interactionsTB outcomesTherapy completionRifampicin administrationViral loadTherapeutic rangePatientsHIVA population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care.
Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G. A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care. Medscape Journal Of Medicine 2006, 8: 72. PMID: 16926811, PMCID: PMC1785162.Peer-Reviewed Original ResearchMeSH KeywordsAdultCross-Sectional StudiesDrug Resistance, Multiple, ViralFemaleHIV InfectionsHumansLongitudinal StudiesMaleRisk-TakingSexual BehaviorConceptsSexual risk behaviorsUnprotected sexual eventsRisk behaviorsSelf-reported sexual risk behaviorDrug resistanceSerial cross-sectional analysisClasses of ARVsMultidrug-resistant HIVHIV-positive patientsAntiretroviral drug classesGenotypic drug resistanceHIV viral loadHIV sexual risk behaviorsHIV drug resistanceDrug-resistant HIVUnprotected sexual behaviorSame time pointsSexual eventsCross-sectional analysisGreat public healthVirologic resultsResistant HIVViral loadActive patientsARV resistance
2005
Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence
Mannheimer S, Matts J, Telzak E, Chesney M, Child C, Wu A, Friedland G, Aids F. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 2005, 17: 10-22. PMID: 15832830, DOI: 10.1080/09540120412331305098.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyART adherenceQOL scoresQuality of lifeTerry Beirn Community ProgramsNewer ART regimensSummary QoL scoresCells/mm3Mean QOL scoreAntiretroviral clinical trialsHigher QoL scoresBaseline CD4ART regimensART-naïveHIV populationMean agePoor adherenceSF-12Clinical trialsImproved QoLClinical researchQoLAdherenceMonthsHIV
1993
A prospective four-year follow-up of neuropsychological function in HIV seropositive and seronegative methadone-maintained patients
Silberstein C, O'Dowd M, Chartock P, Schoenbaum E, Friedland G, Hartel D, McKegney F. A prospective four-year follow-up of neuropsychological function in HIV seropositive and seronegative methadone-maintained patients. General Hospital Psychiatry 1993, 15: 351-359. PMID: 8112557, DOI: 10.1016/0163-8343(93)90001-5.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionCentral nervous system impairmentHIV antibody testingImmunodeficiency virus infectionMethadone-maintained patientsSymptoms/signsNervous system impairmentMethadone maintenance clinicsNeuropsychological Screening BatteryTrail Making B testSubtle cognitive deficitsHIV infectionAntibody testingPhysical examMaintenance clinicsVirus infectionBaseline testingNeuropsychological functionCognitive deficitsNP assessmentFinger tappingSystem impairmentScreening batteryLongitudinal studyPatientsAssociation of Baseline Neuropsychological Function and Progression of Illness Over 4 Years in HIV-Seropositive Individuals
Silberstein C, O’dowd M, Schoenbaum E, Friedland G, Chartock P, Feiner C, Mckegney F. Association of Baseline Neuropsychological Function and Progression of Illness Over 4 Years in HIV-Seropositive Individuals. Journal Of The Academy Of Consultation-Liaison Psychiatry 1993, 34: 502-505. PMID: 8284340, DOI: 10.1016/s0033-3182(93)71824-1.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) disease progressionHIV-positive asymptomatic patientsCentral nervous system impairmentHIV-seropositive individualsNervous system impairmentBaseline neuropsychological functionProgressive HIVAsymptomatic HIVAsymptomatic patientsPoorer baseline scoresImmunologic dysfunctionSystemic symptomsDisease progressionNeuropsychological dysfunctionBaseline scoresNeuropsychological functionHIVPatientsSystem impairmentStudy periodNeuropsychological testsNeuropsychological markersDysfunctionProgressionHigher scores
1991
Human T Lymphotropic Virus Type II (HTLV-II) Infection in a Cohort of New York Intravenous Drug Users: An Old Infection?
Khabbaz R, Hartel D, Lairmore M, Horsburgh C, Schoenbaum E, Roberts B, Hartley T, Friedland G. Human T Lymphotropic Virus Type II (HTLV-II) Infection in a Cohort of New York Intravenous Drug Users: An Old Infection? The Journal Of Infectious Diseases 1991, 163: 252-256. PMID: 1988509, DOI: 10.1093/infdis/163.2.252.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHuman T-lymphotropic virus type II (HTLV-II) infectionHTLV-II infectionType II infectionPolymerase chain reactionRisk factorsHTLV-IIDrug usersHuman immunodeficiency virus (HIV) infectionHIV infection statusImmunodeficiency virus infectionIntravenous drug useMethadone maintenance programTransfusion historyNeedle sharingVirus infectionSerologic resultsSex partnersDrug useShooting galleriesEndemic infectionInfectionOlder ageInfection statusOld infection
1987
A Prospective Longitudinal Study of Neuropsychological and Psychosocial Factors in Asymptomatic Individuals at Risk for Htlv-III/Lav Infection in a Methadone Program: Preliminary Findings
Silberstein C, McKegney F, O'dowd M, Selwyn P, Schoenbaum E, Drucker E, Feiner C, Cox C, Friedland G. A Prospective Longitudinal Study of Neuropsychological and Psychosocial Factors in Asymptomatic Individuals at Risk for Htlv-III/Lav Infection in a Methadone Program: Preliminary Findings. International Journal Of Neuroscience 1987, 32: 669-676. PMID: 3596916, DOI: 10.3109/00207458709043321.Peer-Reviewed Original ResearchConceptsProspective longitudinal studyWAIS similaritiesAssociative learning testHTLV-III/LAV infectionDigit Span ForwardLongitudinal studyImpaired neuropsychological functionLearning TestNeuropsychological functionPsychosocial measuresTest performanceFinger tappingPsychosocial factorsPsychological stressCognitive impairmentPreliminary findingsHTLV-III/LAVIntravenous drug abusersHigh-risk populationAbsence of AIDSDrug useDrug abusersAsymptomatic individualsMethadone programsUnivariate analysis